esume sales of CosMx™ SMI products in Europe.
The UPC Court of Appeal’s decision is a significant win for NanoString and its customers in Europe. The preliminary injunction had been issued as a result of a patent dispute between NanoString and a competitor. With the injunction overturned, NanoString can continue to offer its innovative SMI technology to researchers and scientists in Europe without any further disruption.
NanoString’s CosMx™ SMI products are a cutting-edge tool for spatial biology research, allowing researchers to visualize and analyze gene expression at the single-cell level. This technology enables scientists to gain new insights into complex biological processes and disease mechanisms, ultimately leading to advancements in drug discovery, diagnostics, and personalized medicine.
The decision by the UPC Court of Appeal provides reassurance to NanoString’s customers in Europe that they can continue to rely on NanoString’s SMI technology for their research needs. This is especially important for researchers working in the fields of oncology, immunology, and neuroscience, where spatial biology research plays a crucial role in advancing our understanding of disease and developing new treatment strategies.
“We are pleased with the UPC Court of Appeal’s decision to overturn the preliminary injunction, allowing us to resume sales of our CosMx™ SMI products in Europe,” said Brad Gray, President and CEO of NanoString. “This decision reaffirms NanoString’s commitment to providing innovative solutions to the research community and underscores the value of our SMI technology in advancing scientific discovery.”
In addition to lifting the preliminary injunction, the UPC Court of Appeal also ruled in favor of NanoString on the validity of the patent at the center of the dispute. This decision further solidifies NanoString’s position in the market and strengthens its intellectual property rights related to its SMI technology.
NanoString remains dedicated to driving scientific progress and empowering researchers with cutting-edge tools for spatial biology research. The company continues to invest in research and development to further enhance its SMI technology and expand its product offerings to meet the evolving needs of the research community.
Overall, the decision by the UPC Court of Appeal is a positive development for NanoString and its customers in Europe, providing clarity and certainty around the availability of NanoString’s CosMx™ SMI products for spatial biology research. Researchers and scientists can now confidently rely on NanoString’s innovative technology to drive their research forward and make new discoveries in the field of life sciences.
Source link